Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) have been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $41.25.
AGIO has been the topic of several recent research reports. JPMorgan Chase & Co. upped their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday. Bank of America boosted their target price on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. HC Wainwright upped their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Royal Bank Of Canada raised their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th.
Read Our Latest Research Report on Agios Pharmaceuticals
Insider Activity at Agios Pharmaceuticals
Institutional Investors Weigh In On Agios Pharmaceuticals
A number of institutional investors have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. purchased a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $25,000. Assetmark Inc. grew its stake in shares of Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 362 shares during the period. NewEdge Advisors LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth $49,000. Finally, Eurizon Capital SGR S.p.A. purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth $72,000.
Agios Pharmaceuticals Price Performance
Shares of AGIO opened at $32.27 on Monday. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -4.60 and a beta of 0.58. The firm has a 50 day simple moving average of $34.75 and a 200-day simple moving average of $31.04.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, equities analysts expect that Agios Pharmaceuticals will post -6.12 earnings per share for the current fiscal year.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
Featured Articles
- Five stocks we like better than Agios Pharmaceuticals
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
